Table 4. Comparison of the therapeutic efficacies in the maintenance group.
| Clinical data | X maintenance group |
||||
|---|---|---|---|---|---|
| n | ORR (%) | P value | CBR (%) | P value | |
| Age | 0.064 | 0.764 | |||
| ≥60 years | 13 | 2 (15.4) | 5 (38.5) | ||
| <60 years | 37 | 0 (0) | 16 (43.2) | ||
| Hormone receptor | 1 | 0.009 | |||
| Positive | 31 | 1 (3.2) | 8 (25.2) | ||
| Negative | 19 | 1 (5.3) | 12 (63.2) | ||
| Her-2 | 0.497 | 0.049 | |||
| Positive | 22 | 0 (0) | 5 (22.7) | ||
| Negative | 28 | 2 (7.1) | 16 (50.0) | ||
| Previous treatment | 0.57 | 0.128 | |||
| First-line | 30 | 2 (6.7) | 10 (33.3) | ||
| Second-line and above | 20 | 0 (0) | 11 (55.0) | ||
| Metastatic sites | 1 | 1 | |||
| Viscera | 39 | 2 (5.1) | 16 (41.0) | ||
| Non-viscera | 11 | 0/11 (0) | 5 (45.5) | ||
| DFS | 1 | 0.145 | |||
| >2 years | 23 | 1 (4.3) | 12 (52.2) | ||
| ≤2 years | 27 | 1 (3.6) | 9 (33.3) | ||
X, capecitabine; ORR, overall response rate; CBR, clinical benefit rate; DFS, disease-free survival.